Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies
{{output}}
The discovery of ROS1 and NTRK gene fusions has transformed treatment strategies for a specific group of cancers, particularly non-small cell lung cancer (NSCLC). First-generation tyrosine kinase inhibitors (TKIs) such as crizotinib displayed significant early... ...
